General Stock Ideas

[gfp927z]

Bigworld, On the anti-viral front, Brilacidin looks promising. It's a biomimetic that mimics the body's own innate defensin protein system. It not only works against bacteria like MRSA, but also as a broad spectrum anti-viral. A big plus is that by mimicking the body's defensin protein system, the odds of bacterial or viral resistance developing is extremely small.


Brilacidin -

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165282745


I've been following Brilacidin loosely for over 10 years, when it was first developed at Univ of Penn (Dr. William DeGrado). It's currently in Phase 2 for Covid, with topline data due this month. In addition to some US trial sites, they are also using numerous sites in Russia, and this has the advantage of being out of the FDA's purview so they can't 'deep-six' it if the drug works. Sad that it comes to that, but with Covid, the anti-therapeutic bias is unbelievable, as described by Dr. Peter McCullough -